Education
About Us
Working with TipRanks
Follow Us
Basilea Pharmaceutica (CH:BSLN)
:BSLN
Total Valuation
Basilea Pharmaceutica has a market cap or net worth of CHF640.82M. The enterprise value is CHF716.78M.
Market CapCHF640.82M
Enterprise ValueCHF716.78M
Share Statistics
Basilea Pharmaceutica has 13,320,867 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,320,867
Owned by Insiders―
Owned by Institutions0.11%
Financial Efficiency
Basilea Pharmaceutica’s return on equity (ROE) is 0.31 and return on invested capital (ROIC) is 19.29%.
Return on Equity (ROE)0.31
Return on Assets (ROA)0.14
Return on Invested Capital (ROIC)19.29%
Return on Capital Employed (ROCE)0.22
Revenue Per Employee1.42M
Profits Per Employee245.37K
Employee Count164
Asset Turnover0.82
Inventory Turnover1.82
Valuation Ratios
The current PE Ratio of Basilea Pharmaceutica is 6.8. Basilea Pharmaceutica’s PEG ratio is -0.34.
PE Ratio6.8
PS Ratio2.88
PB Ratio5.22
Price to Fair Value5.22
Price to FCF11.24
Price to Operating Cash Flow12.70
PEG Ratio-0.34
Income Statement
In the last 12 months, Basilea Pharmaceutica had revenue of 232.40M and earned 40.20M in profits. Earnings per share was 3.29.
Revenue232.40M
Gross Profit193.10M
Operating Income51.60M
Pretax Income45.90M
Net Income40.20M
EBITDA51.60M
Earnings Per Share (EPS)3.29
Cash Flow
In the last 12 months, operating cash flow was 50.56M and capital expenditures -2.46M, giving a free cash flow of 48.10M billion.
Operating Cash Flow50.56M
Free Cash Flow48.10M
Free Cash Flow per Share3.61
Dividends & Yields
Basilea Pharmaceutica pays an annual dividend of CHF5, resulting in a dividend yield of ―
Dividend Per ShareCHF5
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.98
52-Week Price Change12.51%
50-Day Moving Average54.89
200-Day Moving Average50.62
Relative Strength Index (RSI)43.18
Average Volume (3m)41.01K
Important Dates
Basilea Pharmaceutica upcoming earnings date is Aug 18, 2026, TBA (Confirmed).
Last Earnings DateFeb 17, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
Basilea Pharmaceutica as a current ratio of 5.11, with Debt / Equity ratio of 78.89%
Current Ratio5.11
Quick Ratio4.68
Debt to Market Cap0.13
Net Debt to EBITDA1.38
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Basilea Pharmaceutica has paid 5.60M in taxes.
Income Tax5.60M
Effective Tax Rate0.12
Enterprise Valuation
Basilea Pharmaceutica EV to EBITDA ratio is 14.33, with an EV/FCF ratio of 12.44.
EV to Sales3.18
EV to EBITDA14.33
EV to Free Cash Flow12.44
EV to Operating Cash Flow11.91
Balance Sheet
Basilea Pharmaceutica has CHF162.34M in cash and marketable securities with CHF100.93M in debt, giving a net cash position of CHF61.41M billion.
Cash & Marketable SecuritiesCHF162.34M
Total DebtCHF100.93M
Net CashCHF61.41M
Net Cash Per ShareCHF4.61
Tangible Book Value Per ShareCHF10.44
Margins
Gross margin is 74.32%, with operating margin of 22.20%, and net profit margin of 17.30%.
Gross Margin74.32%
Operating Margin22.20%
Pretax Margin19.75%
Net Profit Margin17.30%
EBITDA Margin22.20%
EBIT Margin22.20%
Analyst Forecast
The average price target for Basilea Pharmaceutica is CHF69.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF69.00
Price Target Upside31.18% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast58.51%
EPS Growth Forecast―